TXMD (TherapeuticsMD Inc.) stock: $2.19, $25.3M market cap, $9.2M cash, $16.1M EV, $26.8M fully diluted market cap. Data from Fully Diluted's biotech stocks database.
Pipeline assets
IMVEXXY
Approved · Active Modality: small molecule (vaginal estradiol insert)
Target estrogen receptor
Partnerships U.S.: exclusive perpetual license to Mayne Pharma (Dec 2022; 8.0%/7.5% royalties for 20 years, $3M/yr minimum royalties for 12 years, sales milestones up to $30M). Canada: Knight Therapeutics (approved, commercializing since 2024). Ex-U.S. ex-Canada/Israel: Theramex (Israel rights transferred from Knight to Theramex Dec 2024).
Indications- Dyspareunia (moderate-to-severe vulvar and vaginal atrophy due to menopause) (Approved)
Status note Approved vaginal estradiol product for dyspareunia. Company is now a royalty company; all commercial operations discontinued (reflected as discontinued operations since Dec 2022). May 2025 lawsuit against Mayne Pharma for breach of contract over net working capital allowances.
BIJUVA
Approved · Active Modality: small molecule (oral estradiol + progesterone)
Target estrogen + progesterone receptors
Partnerships U.S.: Mayne Pharma (same royalty terms as IMVEXXY). Canada: Knight Therapeutics (approved, commercializing since 2024). Europe: Theramex (regulatory approval in certain European countries since 2021).
Indications- Moderate-to-severe vasomotor symptoms due to menopause (Approved)
Status note Oral bioidentical estradiol/progesterone combination for menopause vasomotor symptoms. Company is now a royalty company; former commercial operations classified as discontinued operations.
ANNOVERA
Approved · Active Modality: vaginal contraceptive ring (segesterone acetate + ethinyl estradiol)
Target progesterone + estrogen receptors
Partnerships Exclusive license to commercialize assigned to Mayne Pharma (with Population Council consent); royalty terms as above.
Indications- Contraception (one-year vaginal system) (Approved)
Status note Approved one-year vaginal contraceptive system; exclusive commercialization license assigned to Mayne Pharma.
Prescription prenatal vitamin products
Approved · Active Modality: prenatal vitamin products
Aliases BocaGreenMD, vitaMedMD
Target n/a
Partnerships U.S.: Mayne Pharma (same royalty terms).
Indications- Prenatal nutrition (Approved)
Status note Prescription prenatal vitamin brands commercialized in the U.S. by Mayne Pharma under the exclusive license.
Per-asset detail extracted from the 10-Q filed 2026-08-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.